Xconomy Report: (Re)generating Excitement

By Gregory T. Huang, Editor, Xconomy Boston

Comments

April 20, 2012

 
CAMBRIDGE, Mass. — A couple of Cambridge companies are gaining ground with their regenerative medicine technology, which uses living cells and other natural materials to promote healing. InVivo Therapeutics says it will soon get the FDA go-ahead to start human trials of its implant for healing spinal cord injuries. Meanwhile, Pervasis Therapeutics, whose technology might help dialysis patients better withstand their treatment, is being acquired by the Irish pharmaceutical giant Shire. Both companies come out of the lab of MIT professor and prolific inventor Robert Langer.
 
In deals news, the venture capital numbers are in from the first quarter of 2012 and Bay State startups continue to outdo their rivals down the coast. In the last three months, VCs invested $650 million in 76 Massachusetts companies compared to just $333 million in 81 companies in New York state. Both states still trail California in VC investment, however.
 
And finally, what’s with all these companies looking to be Facebook killers? The social network is looking a bit vulnerable ahead of its rumored IPO next month. One local startup getting in on the action is Cambridge-based PowerInbox, which is trying to turn email into an interactive platform where you can access social media. Now if it could just get all of our inboxes down to a manageable size. …
 



xconomy logo

 

The weekly roundup of business, technology and life science news from our partners at Xconomy.com airs every Friday on 89.7 Boston Public Radio.

Comment on This Article


Science news

From The World's Science podcast to Nova, we'll deliver updates from these cutting edge programs. See a sample »

   



WGBH Craft Beer Fest, Special Offer